Compare Regeneron Pharmaceuticals Inc (REGN) vs Zillow Group Inc Class A (ZG) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.

The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.

Zillow Group (ZG) trades at $30.00, up 7.26% over 24 hours, but remains in a technical downtrend with bearish moving average signals. The company reported a return to profitability in 2025 with net income of $23 million, though its P/E ratio of 130 is high. Recent earnings have shown volatility, with a miss in Q4 2025 but beats in subsequent quarters. Analyst sentiment is mixed, with a consensus 'Hold' rating and a price target of $48.87, suggesting significant potential upside from the current price.

The outlook for ZG hinges on execution in a challenging housing market. Opportunities include strong revenue growth and market leadership, but risks involve high valuation, affordability headwinds, and intense competition. The stock appears undervalued relative to analyst targets, but investors must weigh the premium valuation against macroeconomic pressures on the housing sector.